I. Beresford

Most-cited papers

1. GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models

   A. Medhurst, Alan R. Atkins, I. Beresford, K. Brackenborough +34 more

   2007Journal of Pharmacology and Experimental Therapeutics299 citations

   Semantic Scholar

   Save

2. Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345

   I. Beresford, P. Birch, R. M. Hagan, S. Ireland

   1991British Journal of Pharmacology220 citations Open access

   Semantic Scholar

   Save

3. Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors

   C. Browning, I. Beresford, Neil J. Fraser, H. Giles

   2000British Journal of Pharmacology129 citations Open access

   Semantic Scholar

   Save

4. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.

   Richard A. Grove, Conn Harrington, Andreas Mahler, I. Beresford +7 more

   2014Current Alzheimer Research104 citations

   Semantic Scholar

   Save

5. Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function.

   R. M. Hagan, S. Ireland, C. Jordan, I. Beresford +2 more

   1991Neuropeptides93 citations

   Semantic Scholar

   Save

6. Signalling by CXC‐chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL‐8 and GROα

   D. A. Hall, I. Beresford, C. Browning, H. Giles

   1999British Journal of Pharmacology84 citations Open access

   Semantic Scholar

   Save

7. The pharmacology of GR203040, a novel, potent and selective non‐peptide tachykinin NK1 receptor antagonist

   D. Beattie, I. Beresford, H. E. Connor, F. Marshall +5 more

   1995British Journal of Pharmacology71 citations Open access

   Semantic Scholar

   Save

8. Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists.

   R. M. Hagan, I. Beresford, J. Stables, J. R. B. Dupere +7 more

   1993Regulatory Peptides60 citations

   Semantic Scholar

   Save

9. Modulation of the rat suprachiasmatic circadian clock by melatonin in vitro

   S. J. Starkey, M. P. Walker, I. Beresford, R. Hagan

   1995NeuroReport52 citations

   Semantic Scholar

   Save

10. GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors.

    I. Beresford, R. L. Sheldrick, D. Ball, M. P. Turpin +5 more

    1995European Journal of Pharmacology48 citations

    Semantic Scholar

    Save

11. GR196429: a nonindolic agonist at high-affinity melatonin receptors.

    I. Beresford, Christopher S. Browning, S. J. Starkey, Jason L. Brown +5 more

    1998Journal of Pharmacology and Experimental Therapeutics41 citations Open access

    Semantic Scholar

    Save

12. The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety

    D. Walsh, Sharon C. Stratton, F. J. Harvey, I. Beresford +1 more

    1995Psychopharmacology41 citations

    Semantic Scholar

    Save

13. Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box.

    Sharon C. Stratton, I. Beresford, F. J. Harvey, M. P. Turpin +2 more

    1993European Journal of Pharmacology40 citations

    Semantic Scholar

    Save

14. Ontogeny and characterization of [125I]Bolton Hunter-eledoisin binding sites in rat spinal cord by quantitative autoradiography.

    I. Beresford, S. Ireland, J. Stables, R. M. Hagan

    1992Neuroscience29 citations

    Semantic Scholar

    Save

15. Treatments for stroke

    I. Beresford, A. A. Parsons, A. Hunter

    2003Expert Opinion on Emerging Drugs26 citations

    Semantic Scholar

    Save

16. Synthesis and characterization of selective fluorescent ligands for the neurokinin NK2 receptor.

    Charles G. Bradshaw, K. Ceszkowski, Gerardo Turcatti, I. Beresford +1 more

    1994Journal of Medicinal Chemistry25 citations Open access

    Semantic Scholar

    Save

17. Striatal lesions and transplants demonstrate that cholecystokinin receptors are localized on intrinsic striatal neurones: a quantitative autoradiographic study.

    I. Beresford, M. D. Hall, C. Clark, R. Hill +2 more

    1987Neuropeptides24 citations

    Semantic Scholar

    Save

18. New spiropiperidines as potent and selective non-peptide tachykinin NK2 receptor antagonists.

    Paul W. Smith, A. Cooper, R. Bell, I. Beresford +7 more

    1995Journal of Medicinal Chemistry23 citations

    Semantic Scholar

    Save

19. GR138676, a novel peptidic tachykinin antagonist which is potent at NK3 receptors.

    J. Stables, I. Beresford, S. Arkinstall, S. Ireland +4 more

    1994Neuropeptides22 citations

    Semantic Scholar

    Save

20. Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.

    David M. Wilson, J. Apps, N. Bailey, M. Bamford +27 more

    2013Bioorganic & Medicinal Chemistry Letters20 citations Open access

    Semantic Scholar

    Save

21. Low molecular weight neurokinin NK2 antagonists

    P. W. Smith, A. Mcelroy, J. Pritchard, M. J. Deal +8 more

    199317 citations

    Semantic Scholar

    Save

22. Development of a Homogeneous MAP Kinase Reporter Gene Screen for the Identification of Agonists and Antagonists at the CXCR1 Chemokine Receptor

    S. Rees, D. P. Martin, Sarah V. Scott, Sue Brown +3 more

    2001Journal of biomolecular screening16 citations Open access

    Semantic Scholar

    Save

23. Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude.

    W. J. Drijfhout, J. D. de Vries, E. Homan, H. F. Brons +6 more

    1999European Journal of Pharmacology11 citations

    Semantic Scholar

    Save

24. Pharmacological characterisation of melatonin mt1 receptor-mediated stimulation of [35S]-GTPgammaS binding.

    I. Beresford, F. J. Harvey, D. A. Hall, H. Giles

    19989 citations

    Semantic Scholar

    Save

25. Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion.

    Anthony B. Hawcock, I. Beresford, F. Marshall, R. M. Hagan

    1995European Journal of Pharmacology9 citations

    Semantic Scholar

    Save

26. A novel peptidic tachykinin antagonist which is potent at NK3 receptors

    J. Stables, S. Arkinstall, I. Beresford, P. Seale +2 more

    19937 citations

    Semantic Scholar

    Save

27. The discovery of the benzazepine class of histamine H3 receptor antagonists.

    David M. Wilson, J. Apps, N. Bailey, M. Bamford +22 more

    2013Bioorganic & Medicinal Chemistry Letters5 citations Open access

    Semantic Scholar

    Save

28. Antinociceptive effects of the non-peptide NK1 antagonist (±)CP-99,994 in the gerbil

    P. Elliott, G. D. Smith, J. Bowers, J. Wiseman +4 more

    19933 citations

    Semantic Scholar

    Save

29. Profile of activity of NK1 receptor antagonists in nociceptive tests

    P. Birch, I. Beresford, J. Bowers, S. Harrison +2 more

    19933 citations

    Semantic Scholar

    Save

30. Two NK1 agonist responses in the rat superior cervical ganglion

    A. B. Hawcock, F. Marshall, I. Beresford, R. Hagan

    19933 citations

    Semantic Scholar

    Save

31. NK2 antagonists and the role of NK2 receptors

    R. M. Hagan, I. Beresford, P. Elliott, D. Ball +5 more

    19922 citations

    Semantic Scholar

    Save

32. Pharmacological characterisation of -melatonin binding to human recombinant melatonin Mel-1A and Mel-1B receptors

    C. Browning, J. Brown, I. Beresford, H. Giles

    19971 citations

    Semantic Scholar

    Save

33. Lack of effect of a selective NK2 receptor antagonist in acute nociceptive tests

    P. Birch, I. Beresford, J. Bowers, R. Hagan +2 more

    19931 citations

    Semantic Scholar

    Save

34. A randomized, double-blind, placebo-controlled 16 week study of the H3 receptor antagonist GSK239512 in subjects with mild-to-moderate Alzheimer's disease (AD)

    Richard A. Grove, J. Horrigan, Conn Harrington, I. Beresford +1 more

    2011Alzheimer's & Dementia0 citations

    Semantic Scholar

    Save

35. Central & Peripheral Nervous Systems

    I. Beresford, A. A. Parsons, A. Hunter

    20030 citations

    Semantic Scholar

    Save

36. Pharmacological characterisation of melatonin mt1 receptor-mediated stimulation of [35S]-GTPgammaS binding.

    I. Beresford, F. J. Harvey, D. A. Hall, H. Giles

    1998Biochemical Pharmacology0 citations

    Semantic Scholar

    Save

37. GR159897; a potent and selective non-peptide NK2 antagonist

    H. S. Adams, D. Ball, R. Bell, I. Beresford +15 more

    19930 citations

    Semantic Scholar

    Save

38. Characterization of NK2 receptors in human ileum and localization in rat brain using the NK2 antagonist radioligand [3H]-GR100679

    I. Beresford, J. Dupere, J. Stables, A. Chollet +1 more

    19930 citations

    Semantic Scholar

    Save

39. Involvement of NK-1 receptors in neurokinin-induced plasma extravasation (PEV) in rat skin

    I. Beresford, M. Balsat, R. M. Hagan, C. Jordan

    19890 citations

    Semantic Scholar

    Save